Cardiovascular Disease Epidemiology in Patients with Lupus

项目摘要/摘要 凯伦·科斯滕巴德博士是一位公认的以患者为导向的流行病学和预后研究员。 系统性红斑狼疮和类风湿性关节炎，以及下一代 以病人为中心的临床研究人员。她已经担任了40年的预科和中级研究导师 博士后研究实习生。以及她作为布里格姆妇女医院院长的职位 狼疮计划，科斯滕巴德博士的指导是由她在哈佛大学的多个附属机构提供的 机构和培训计划，以及国家研究和临床组织。候选人中有很多人 持续的以患者为导向的研究项目和合作，高度致力于指导和 继续提高她的指导技能，以及卓越的机构资源，为她提供了一个杰出的 为初级调查人员的发展创造环境。这笔K24拨款将保留科斯滕巴德博士的 保护她的时间，免除她的临床和行政责任。提出了新的研究目标 将建立在过去关于狼疮患者心血管疾病风险的工作基础上。其数据超过 在美国，10万名狼疮患者登记在医疗补助计划中，新研究将解决关键问题 关于狼疮疾病异质性和心血管疾病风险的问题，具有丰富的统计能力 发现这些严重后果之间的差异。这一人群固有的社会人口差异和 在这一脆弱人群中心血管疾病的高风险使这些研究与 改善狼疮患者的护理和预后。此外，验证和完善2017年QRISK3 心血管疾病风险预测算法在Brigham和女性狼疮队列中将为患者提供 收集和验证结果的互动，以及指导对象制定风险预测的经验 算法。要检查的临床问题将提供独立的项目和出版物、经验 为研究学员提供先进的生物统计学模型，并提供极好的指导机会。Dr。 科斯滕巴德已经组建了一支由高素质的联合导师组成的强大团队，她将招聘两到三名新的 每年参加她的风湿病流行病学和结果研究计划的受训人员。她会继续 使用学员反馈和许多教育机会来完善她的指导计划和技能 她的环境。这笔K24拨款将支持科斯滕巴德博士开发下一代 以病人为导向的风湿病研究人员。

PROJECT SUMMARY/ABSTRACT Dr. Karen Costenbader is a recognized patient-oriented investigator in the epidemiology and outcomes of systemic lupus erythematosus and rheumatoid arthritis, and a very engaged mentor of the next generation of patient-oriented clinical investigators. She has served as primary or secondary research mentor for 40 pre- and post-doctoral research trainees. Along with her position as Director of the Brigham and Women's Hospital Lupus Program, Dr. Costenbader's mentoring is facilitated by her affiliations with multiple Harvard-based institutions and training programs, and with national research and clinical organizations. The candidate's many ongoing patient-oriented research projects and collaborations, high degree of commitment to mentoring and to continuing to improve her mentoring skills, and the exceptional institutional resources, provide an outstanding environment for the development of junior investigators. This K24 grant would preserve Dr. Costenbader's protected time and relieve her of clinical and administrative responsibilities. The new research aims proposed will build upon past work on cardiovascular disease risk among lupus patients. With data on more than 100,000 lupus patients enrolled in Medicaid in the U.S., the new studies will address key unanswered questions about lupus disease heterogeneity and cardiovascular disease risk, with abundant statistical power to detect differences in these serious outcomes. The inherent sociodemographic variation of this population and the high risk of cardiovascular disease in this vulnerable population make these studies extremely relevant for improving care and outcomes for lupus patients. Additionally, validating and refining the 2017 QRISK3 cardiovascular disease risk prediction algorithm in the Brigham and Women's Lupus Cohort will provide patient interactions to collect and verify outcomes, and experience for mentees with developing risk prediction algorithms. The clinical questions to be examined will afford independent projects and publications, experience with advanced biostatistical models for research mentees, and excellent mentoring opportunities. Dr. Costenbader has assembled a strong team of highly qualified co-mentors and she will recruit two to three new trainees into her rheumatic disease epidemiology and outcomes research program annually. She will continue to refine her mentoring program and skills using trainee feedback and the many educational opportunities in her environment. This K24 grant would support Dr. Costenbader's ability to develop the next generation of patient-oriented rheumatic disease investigators.